LearnOptimizeInsightsSignalsInstitutional (Soon)Ask (Soon)Comparisons
Index Battle · Evidence-first comparison

Nasdaq-100 vs Nikkei 225: Which Exposure Fits Your Portfolio?

Compare their structural exposure, diversification and intended portfolio role—without treating recent performance as a decision rule.

Last reviewed: 26 August 2026IndependentNo paid placementsInformational only

index

Nasdaq-100

Large non-financial Nasdaq-listed companies

vs

index

Nikkei 225

Japanese blue-chip equities

Overall verdict

Nasdaq-100 provides large non-financial nasdaq-listed companies, while Nikkei 225 provides japanese blue-chip equities. The decision is primarily about geographic or asset-class exposure, not which has recently performed better.

Quick Decision

Choose Nasdaq-100 if…

you deliberately want large non-financial nasdaq-listed companies and it matches the intended portfolio role.

Choose Nikkei 225 if…

you deliberately want japanese blue-chip equities and accept its distinct concentration and risks.

Either can make sense if…

the exposure, implementation and risks fit a clearly defined portfolio objective.

At a glance

Entity characteristics—not reference-product fees.

CharacteristicNasdaq-100Nikkei 225
ExposureLarge non-financial Nasdaq-listed companiesJapanese blue-chip equities
GeographyUnited StatesJapan
Market coverageLarge capLarge cap
Emerging marketsNot includedNot included
Small capsNot includedNot included
WeightingModified market-cap weightedPrice weighted
Index providerNasdaqNikkei

Key differences

  1. 1.Exposure: Large non-financial Nasdaq-listed companies compared with Japanese blue-chip equities.
  2. 2.Geography: United States compared with Japan.
  3. 3.Weighting: Modified market-cap weighted compared with Price weighted.
  4. 4.Index provider: Nasdaq compared with Nikkei.

Decision scorecard

ExposureDepends
GeographyDepends
WeightingDepends
Index providerDepends

“Depends” means the category reflects an investor objective, not universal superiority.

Coverage, countries and sectors

Verified holdings, concentration, country and sector datasets are not currently connected. When available, each dataset will be labelled as official index data or Reference ETF holdings; listing domicile will not be presented as economic revenue exposure.

What this means in a portfolio

Holding both does not automatically create two independent portfolios. Overlapping companies and regions can make the combination an intentional tilt toward the exposure emphasised by Nikkei 225.

Common mistake

Assuming that adding Nikkei 225 to Nasdaq-100 automatically improves diversification, without checking overlap and concentration.

Historical comparison basis

Historical performance is represented using Grovcap-selected reference exchange-traded products. It is not the official index or spot return series. Fund or ETP returns can differ because of fees, taxes, tracking, cash positions, product structure and other implementation effects. Differences can reflect TER, tracking difference, withholding taxes, sampling, securities lending, cash drag, operating expenses, currency conversion and inception date.

No period is currently comparable across both reference products on a like-for-like currency, basis and reporting-date footing, so no return figures are shown. Grovcap never renders a missing return as 0.00%.

Grovcap does not currently hold a daily net-asset-value time series for these products. Indexed performance charts, annualised volatility, maximum drawdown and return-per-risk therefore remain unavailable rather than being estimated from period returns.

Reference instruments used

One canonical European exchange-traded product per exposure, chosen by published rules: exact benchmark family, active and published, plain long-only, then accumulating, unhedged, longest usable history and largest established product.

Nasdaq-100 reference product

iShares NASDAQ 100 UCITS ETF

ISIN
IE00B53SZB19
Product type
UCITS ETF
Provider
Ishares
Tracked benchmark
NASDAQ 100 Index
Distribution
Accumulating
Currency hedging
Unhedged
Replication
Replicated
Domicile
Ireland
Base currency
USD
Ongoing charge (TER)
0.30%
Fund size
$26.89bn
Inception
26 Jan 2010

Selected deterministically from 15 eligible products in the Grovcap database — never by commercial arrangement.

Nikkei 225 reference product

iShares Nikkei 225 UCITS ETF

ISIN
IE00B52MJD48
Product type
UCITS ETF
Provider
Ishares
Tracked benchmark
Nikkei 225 Net Index in JPY
Distribution
Accumulating
Currency hedging
Unhedged
Replication
Replicated
Domicile
Ireland
Base currency
JPY
Ongoing charge (TER)
0.48%
Fund size
JPY 107.97bn
Inception
25 Jan 2010

Selected deterministically from 4 eligible products in the Grovcap database — never by commercial arrangement.

Why these reference instruments?

Continue researching

Related Grovcap guides, rankings and tools to take the next step.

Disclaimer

The information provided by Grovcap is for informational and educational purposes only and does not constitute investment, financial, legal, or tax advice. Investing involves risk, including the possible loss of capital. Always conduct your own research or consult a qualified professional before making investment decisions.

Your responses to quizzes, surveys, and other interactive features may be used in aggregated and anonymized form to improve Grovcap and generate investor insights. We do not sell personally identifiable information to third parties. For more information about how we collect, use, and protect your data, please refer to our Privacy Policy.